2024 |
New Lethal Combinations and Clinical Challenges
|
Session Description:
Methamphetamine and cocaine use rates and overdose deaths are rapidly increasing in much of the US. Over 50% of overdose deaths in the US now involve use of stimulants, alone or in combination with fentanyl and/or xylazine. The presentation will review the clinical challenges presented by individuals who use stimulants and current protocols for addressing acute medical/psychiatric conditions. Evidence-based behavioral/psychosocial strategies are presented, along with pharmacotherapies currently considered promising. Fentanyl and xylazine have changed the illicit drug landscape and made harm reduction the essential framework for addressing the needs of individuals who use illicit drugs. Information will be provided on the changing mixture of drugs being used, the effects of these drugs, the challenges that the use of these drugs provide to first responders, medical professionals and addiction treatment providers.
Methamphetamine and cocaine use rates and overdose deaths are rapidly increasing in much of the US. Over 50% of overdose deaths in the US now involve use of stimulants, alone or in combination with fentanyl and/or xylazine. The presentation will review the clinical challenges presented by individuals who use stimulants and current protocols for addressing acute medical/psychiatric conditions. Evidence-based behavioral/psychosocial strategies are presented, along with pharmacotherapies currently considered promising. Fentanyl and xylazine have changed the illicit drug landscape and made harm reduction the essential framework for addressing the needs of individuals who use illicit drugs. Information will be provided on the changing mixture of drugs being used, the effects of these drugs, the challenges that the use of these drugs provide to first responders, medical professionals and addiction treatment providers.
This is one training offered twice, so you can choose which one to attend based off of what works best for your schedule.
These sessions will not be recorded, so you will have to attend them live.
Trainers: Dr. Richard Rawson & Al Hasson, MSW
Richard A. Rawson, Ph.D., is Professor Emeritus at the UCLA Department of Psychiatry and a Research Professor at the Vermont Center for Behavior and Health at the University of Vermont. He received a Ph.D. in experimental psychology from the University of Vermont in 1974. Dr. Rawson conducted numerous clinical trials on pharmacological and psychosocial/behavioral addiction treatments for the treatment of individuals with cocaine and methamphetamine disorders. He has represented the US at numerous international meetings on methamphetamine. He has led addiction research and training projects for the United Nations, the World Health Organization, and the U.S. State Department, exporting science-based knowledge to many parts of the world. He is a member of the Motivational Incentives Policy Group, a volunteer group that is working to reduce obstacles to the use of contingency management for treatment of stimulant use disorder. He is currently providing technical assistance to 8 states on the development of treatment services for individuals with stimulant use disorder. Dr. Rawson has published 3 books, 40 book chapters, and over 250 peer-reviewed articles and has conducted many workshops, paper presentations, and training sessions.
Albert L. Hasson, MSW, ADDICTION RESEARCHER AND TREATMENT PROVIDER, UCLA, LOS ANGELES, CA
Albert L. Hasson received his MSW from the University of California – Los Angeles (UCLA) and has worked in the field of addiction medicine as a researcher, treatment provider, and trainer since 1977. He began his career working as a research associate at the Sepulveda Veterans Administration Medical Center evaluating naltrexone for the treatment of opioid use disorders. Mr. Hasson participated in the development of the evidence-based Matrix Model, a cognitive behavioral intervention for the treatment of stimulant disorders, and established the Matrix Institute on Addictions, Los Angeles, an opioid treatment program serving individuals with co-occurring mental and physical health and substance use disorders. During his role as the Node Coordinator of the Pacific Region Node of the National Institute on Drug Abuse, Clinical Trials Network, Mr. Hasson provided oversight for the development and conduct of large, multi-site clinical trials evaluating medications and behavioral therapies for substance use disorders. As a project director and trainer for the Pacific Southwest Addiction Technology Transfer Center at the UCLA Integrated Substance Abuse Programs, Mr. Hasson trained mental health, corrections, and substance use disorder providers on evidence-based interventions, including Motivational Interviewing, Cognitive Behavioral Therapy, Contingency Management, medications for opioid use disorder, and the American Society of Addiction Medicine Criteria. Mr. Hasson recently retired from the UCLA Integrated Substance Abuse Programs and is currently working as a private consultant to a number of State agencies around the country.
Albert L. Hasson, MSW, ADDICTION RESEARCHER AND TREATMENT PROVIDER, UCLA, LOS ANGELES, CA
Albert L. Hasson received his MSW from the University of California – Los Angeles (UCLA) and has worked in the field of addiction medicine as a researcher, treatment provider, and trainer since 1977. He began his career working as a research associate at the Sepulveda Veterans Administration Medical Center evaluating naltrexone for the treatment of opioid use disorders. Mr. Hasson participated in the development of the evidence-based Matrix Model, a cognitive behavioral intervention for the treatment of stimulant disorders, and established the Matrix Institute on Addictions, Los Angeles, an opioid treatment program serving individuals with co-occurring mental and physical health and substance use disorders. During his role as the Node Coordinator of the Pacific Region Node of the National Institute on Drug Abuse, Clinical Trials Network, Mr. Hasson provided oversight for the development and conduct of large, multi-site clinical trials evaluating medications and behavioral therapies for substance use disorders. As a project director and trainer for the Pacific Southwest Addiction Technology Transfer Center at the UCLA Integrated Substance Abuse Programs, Mr. Hasson trained mental health, corrections, and substance use disorder providers on evidence-based interventions, including Motivational Interviewing, Cognitive Behavioral Therapy, Contingency Management, medications for opioid use disorder, and the American Society of Addiction Medicine Criteria. Mr. Hasson recently retired from the UCLA Integrated Substance Abuse Programs and is currently working as a private consultant to a number of State agencies around the country.
